[Translation] A multicenter, randomized, double-blind, parallel controlled clinical trial on the efficacy and safety of liranapthate cream in the treatment of tinea corporis and tinea pedis

与1％布替萘芬软膏进行对照，评价2％利拉萘酯乳膏治疗体股癣、足癣的疗效和安全性

[Translation]

To evaluate the efficacy and safety of 2% liranapthate cream in the treatment of tinea corporis and tinea pedis by comparing it with 1% butenafine ointment

Start Date18 Sep 2006

Sponsor / Collaborator

Beijing Lingrui Weiya Technology Co. Ltd.

[+1]

100 Clinical Results associated with Liranaftate

100 Translational Medicine associated with Liranaftate

100 Patents (Medical) associated with Liranaftate

Literatures (Medical) associated with Liranaftate

01 Dec 2024·Fundamental & Clinical Pharmacology

Nociceptive TRP channels function as molecular target for several antifungal drugs

Article

Author: Hashimoto, Miho ; Okabe, Shota ; Ohta, Toshio ; Takahashi, Kenji

AbstractBackground/objectivesTopically applied antifungal agents can induce adverse effects, such as pain and irritation. The transient receptor potential (TRP) channels—TRPA1 and TRPV1—mainly expressed in sensory neurons, act as sensors for detecting irritants. This study aims to evaluate the involvement of nociceptive channels in topical antifungal‐induced pain and irritation. We tested nine topical antifungals belonging five classes: isoconazole, econazole, miconazole, clotrimazole, and ketoconazole as imidazoles; liranaftate as a thiocarbamate; terbinafine as an allylamine; amorolfine as a morpholine; and butenafine as a benzylamine.MethodsIntracellular calcium concentrations ([Ca2+]i) and membrane currents in response to antifungals were measured to estimate channel activity using heterologously expressing cells and isolated mouse sensory neurons.ResultsIn mouse TRPA1‐expressing cells, all the tested drugs induced an increase in [Ca2+]i, which was abrogated or reduced by a TRPA1 blocker. Although many drugs evoked the TRPA1‐nonspecific [Ca2+]i response at high concentrations, responses to clotrimazole, ketoconazole, and liranaftate were TRPA1 specific and elicited current responses in TRPA1‐expressing cells. In mouse TRPV1‐expressing cells, clotrimazole and ketoconazole elicited [Ca2+]i and current responses. In mouse sensory neurons, liranaftate‐induced increase in [Ca2+]i was abrogated by a TRPA1 blocker and Trpa1 deletion. Responses to ketoconazole were inhibited by TRPA1 and TRPV1 blockers and by the genetic deletion of either channel.ConclusionThese results suggest that topical antifungal‐induced pain and irritation are attributable to the activation of nociceptive TRPA1 and/or TRPV1 channel/s. Consequently, caution should be exercised in the use of topical antifungals with symptoms of pain.

01 Jun 2022·Experimental Biology and Medicine

Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma

Article

Author: Liu, Min ; Li, Guo-hui ; Le, Kai-di ; Ma, Ying-lin ; Yan, Jia-qing ; Dong, Bin

Platinum-based chemotherapy, especially carboplatin, is the primary measure to treat patients with ovarian cancer (OC). However, OC patients still have an adverse prognosis due to emergency of chemotherapy resistance. Ovarian serous cystadenocarcinoma (OSC) is the most common histological subtype of OC. Therefore, identifying the key factors that affect chemotherapy resistance and searching novel treatments had become a top priority. In this study, we analyzed carboplatin response-related mRNA, miRNA, DNA methylation, and alternative splicing (AS) and established a drug-resistant signature for carboplatin in OSC. This drug-resistant signature was obviously higher in resistant group than in non-resistant group and had accuracy predictive performance, which demonstrated that this signature could be considered as a superior indicator for OSC patients with carboplatin resistance. Furthermore, we selected three potential small molecule drugs including liranaftate, siguazodan, and tramiprostate to inhibit carboplatin resistance of OSC. In addition, we also identified ZINC00000205417, ZINC00000140928, and ZINC00021908260 were potential small molecule compounds for SLC17A7 based on Molecular Operating Environment (MOE) virtual screening. Finally, we confirmed the drug-like properties of these small molecule drugs via evaluating absorption, distribution, metabolism, elimination, and toxicity (ADMET) property. In summary, the signature could be used as biomarker for carboplatin resistance and small molecule drugs targeting these genes could improve clinical treatment for OSC in the future.

01 Feb 2020·Mycoses

Anti‐inflammatory effect of lanoconazole on 12‐O‐tetradecanoylphorbol‐13‐acetate‐ and 2,4,6‐trinitrophenyl chloride–induced skin inflammation in mice

Article

Author: Matsumoto, Tatsumi ; Nozawa, Naoki ; Hashimoto, Kei ; Yamada, Yoshihito ; Nakamura, Aki ; Uratsuji, Hideya

SummaryBackgroundLanoconazole (LCZ) is a topical antifungal agent clinically used to treat fungal infections such as tinea pedis. LCZ has not only antifungal effects but also anti‐inflammatory effects, which have the potential to provide additional clinical benefits. However, the characteristic features of the inhibitory effects of LCZ on skin inflammation remain unclear.ObjectiveWe evaluated the inhibitory effects of topical application of LCZ, and compared the effects of LCZ with those of other antifungal agents including liranaftate, terbinafine and amorolfine.MethodsEach antifungal agent was topically applied on 12‐O‐tetradecanoylphorbol‐13‐acetate‐induced irritant dermatitis and 2,4,6‐trinitrophenyl chloride‐induced contact dermatitis in mice (BALB/c). The ear thickness, myeloperoxidase activity and inflammatory mediator contents were evaluated.ResultsLCZ dose‐dependently suppressed 12‐O‐tetradecanoylphorbol‐13‐acetate‐induced irritant dermatitis, suppressed the production of neutrophil chemotactic factors such as keratinocyte‐derived chemokine and macrophage inflammatory protein‐2, and inhibited neutrophil infiltration to the inflammation site. Moreover, 1% LCZ reduced the ear swelling in mice with 2,4,6‐trinitrophenyl chloride‐induced contact dermatitis in accordance with the inhibition of interferon‐γ production. The inhibitory potency of LCZ on these types of dermatitis in mice was stronger than that of other types of antifungal agents.ConclusionThe anti‐inflammatory effects of LCZ were exerted through the inhibition of inflammatory mediator production. These effects may contribute to the relief of dermatitis symptoms in patients with tinea pedis.

100 Deals associated with Liranaftate

External Link

KEGG	Wiki	ATC	Drug Bank
D01550	Liranaftate	D01A	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Tinea corporis	JP	Torii Pharmaceutical Co., Ltd.	25 Jul 2000
Tinea corporis	JP	Zenyaku Kogyo Co., Ltd.	25 Jul 2000
tinea cruris	JP	Torii Pharmaceutical Co., Ltd.	25 Jul 2000
tinea cruris	JP	Zenyaku Kogyo Co., Ltd.	25 Jul 2000
Tinea Pedis	JP	Torii Pharmaceutical Co., Ltd.	25 Jul 2000
Tinea Pedis	JP	Zenyaku Kogyo Co., Ltd.	25 Jul 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
tinea cruris	Preclinical	CN	Beijing Lingrui Weiya Technology Co. Ltd.	18 Sep 2006
tinea cruris	Preclinical	CN	Beijing Guolian Chenghui Medicine Technology Co., Ltd.	18 Sep 2006
Tinea Pedis	Preclinical	CN	Beijing Guolian Chenghui Medicine Technology Co., Ltd.	18 Sep 2006
Tinea Pedis	Preclinical	CN	Beijing Lingrui Weiya Technology Co. Ltd.	18 Sep 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis